Literature DB >> 17399779

Eosinophilic disorders.

Dagmar Simon1, Hans-Uwe Simon.   

Abstract

Eosinophilic inflammatory responses occur in association with multiple disorders. Although the initial cause and the affected organs vary among the different eosinophilic disorders, there are only 2 major pathways that mediate eosinophilia: (1) cytokine-mediated increased differentiation and survival of eosinophils (extrinsic eosinophilic disorders), and (2) mutation-mediated clonal expansion of eosinophils (intrinsic eosinophilic disorders). Independent from the original trigger, the most common cause of eosinophilia is the increased generation of IL-5-producing T cells. In some cases, tumor cells are the source of eosinophil hematopoietins. The intrinsic eosinophilic disorders are characterized by mutations in pluripotent or multipotent hematopoietic stem cells leading to chronic myeloid leukemias with eosinophils as part of the clone. Here, we propose a new classification of eosinophilic disorders on the basis of these obvious pathogenic differences between the 2 groups of patients. We then discuss many known eosinophilic disorders, which can be further subdivided by differences in T-cell activation mechanisms, origin of the cytokine-producing tumor cell, or potency of the mutated stem cell. Interestingly, many subgroups of patients originally thought to have the idiopathic hypereosinophilic syndrome can be integrated in this classification.

Entities:  

Mesh:

Year:  2007        PMID: 17399779     DOI: 10.1016/j.jaci.2007.02.010

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  41 in total

Review 1.  Approach to patients with eosinophilia.

Authors:  Lanny J Rosenwasser
Journal:  Mo Med       Date:  2011 Sep-Oct

2.  Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation.

Authors:  Alice Soragni; Shida Yousefi; Christina Stoeckle; Angela B Soriaga; Michael R Sawaya; Evelyne Kozlowski; Inès Schmid; Susanne Radonjic-Hoesli; Sebastien Boutet; Garth J Williams; Marc Messerschmidt; M Marvin Seibert; Duilio Cascio; Nadia A Zatsepin; Manfred Burghammer; Christian Riekel; Jacques-Philippe Colletier; Roland Riek; David S Eisenberg; Hans-Uwe Simon
Journal:  Mol Cell       Date:  2015-02-26       Impact factor: 17.970

Review 3.  Origin, regulation and physiological function of intestinal oeosinophils.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

4.  Eosinophilia in a cat with acute leukemia.

Authors:  Cornelia Gilroy; María Forzán; Anne Drew; William Vernau
Journal:  Can Vet J       Date:  2011-09       Impact factor: 1.008

Review 5.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

6.  RhoH is a negative regulator of eosinophilopoiesis.

Authors:  Christina Stoeckle; Barbara Geering; Shida Yousefi; Saša Rožman; Nicola Andina; Charaf Benarafa; Hans-Uwe Simon
Journal:  Cell Death Differ       Date:  2016-10-14       Impact factor: 15.828

7.  Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.

Authors:  Yanhua Liang; Rosemarie E Seymour; John P Sundberg
Journal:  J Invest Dermatol       Date:  2010-09-02       Impact factor: 8.551

Review 8.  Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract.

Authors:  Dagmar Simon; Andrew Wardlaw; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

9.  Eosinophilia and parotitis occurring early in clozapine treatment.

Authors:  Bochra Nourhène Saguem; Saoussen Bouhlel; Chaker Ben Salem; Bechir Ben Hadj Ali
Journal:  Int J Clin Pharm       Date:  2015-09-15

Review 10.  Novel targeted therapies for eosinophilic disorders.

Authors:  Michael E Wechsler; Patricia C Fulkerson; Bruce S Bochner; Gail M Gauvreau; Gerald J Gleich; Tim Henkel; Roland Kolbeck; Sameer K Mathur; Hector Ortega; Jatin Patel; Calman Prussin; Paolo Renzi; Marc E Rothenberg; Florence Roufosse; Dagmar Simon; Hans-Uwe Simon; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.